Business OperationsThe company received a Termination Process Letter to withdraw the Evomela license following a wind-down period, which impacts the company's Chinese business revenues.
EarningsCASI reported a net loss of $0.69 per share for the quarter, which is higher than the consensus estimated net loss of $0.61 per share.
RevenueThe company reported lower-than-expected revenues, which fell 16% year-over-year, primarily due to increased generic competition for Evomela in China.